Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease

Human Gene Therapy. Clinical Development
Stéphane PalfiKyriacos A Mitrophanous

Abstract

Parkinson's disease is typically treated with oral dopamine replacement therapies. However, long-term use is complicated by motor fluctuations from intermittent stimulation of dopamine receptors and off-target effects. ProSavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a Phase I/II first-in-human study, with significant improvements in motor behavior from baseline at 1 year. Here, patients with Parkinson's disease from the open-label trial were followed up in the long term to assess the safety and efficacy of ProSavin after bilateral injection into the putamen. Fifteen patients who were previously treated with ProSavin have been followed for up to 5 years, with some having been seen for 8 years. Eight patients received deep brain stimulation at different time points, and their subsequent assessments continued to assess safety. Ninety-six drug-related adverse events were reported (87 mild, 6 moderate, 3 severe) of which more than half occurred in the first year. The most common drug-related events were dyskinesias (33 events, 11 patients) and on-off phenomena (22 events, 11 patients). A significant improvement in the defined "off" Unified Par...Continue Reading

References

Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·J E Ahlskog, M D Muenter
Sep 4, 2003·Annals of Neurology·C Warren OlanowThomas B Freeman
May 23, 2006·Lancet Neurology·Lonneke M L de Lau, Monique M B Breteler
Jun 27, 2009·Neurologic Clinics·Anthony H V Schapira
Apr 7, 2010·Science Translational Medicine·Béchir JarrayaStéphane Palfi
Jul 8, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Shin-ichi MuramatsuImaharu Nakano
Sep 13, 2011·International Review of Neurobiology·L K PrashanthWassilios G Meissner
Oct 12, 2012·PloS One·Carsten EggersLars Timmermann
Jul 30, 2016·Human Gene Therapy. Clinical Development·Hannah J StewartKyriacos A Mitrophanous
Oct 7, 2016·Human Gene Therapy·Peter A CampochiaroKyriacos A Mitrophanous

❮ Previous
Next ❯

Citations

Jul 25, 2019·Human Molecular Genetics·Ziying YanJohn F Engelhardt
Jan 21, 2020·Glia·Hélène HirbecCarole Escartin
Jan 8, 2020·Nature Reviews. Neuroscience·Malin ParmarClaire Henchcliffe
Mar 7, 2019·Epilepsy Currents·Selene IngusciMichele Simonato
Jun 11, 2020·International Journal of Molecular Sciences·Rami Ahmad ShahrorKai-Yun Chen
Jul 18, 2019·Frontiers in Pharmacology·Selene IngusciMichele Simonato
Nov 9, 2019·Pharmaceutics·Alisa A ShaimardanovaValeriya V Solovyeva
Apr 5, 2020·Cells·Simoneide S Titze-de-AlmeidaRicardo Titze-de-Almeida
Aug 21, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·C Warren OlanowJose A Obeso
Dec 26, 2018·Journal of Parkinson's Disease·Tomas Björklund
Mar 31, 2019·Gene Therapy·Daniela Blanco-OcampoHugo Peluffo
Jul 8, 2020·Gene Therapy·Morgane HumbelNicole Déglon
Aug 1, 2020·Journal of Neurology, Neurosurgery, and Psychiatry·R Mark RichardsonPaul S Larson
Sep 20, 2020·Biomolecules·Loredana LeggioNunzio Iraci
Nov 1, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Philip C Buttery, Roger A Barker
Oct 23, 2020·Biotechnology Journal·Ana Sofia MoreiraCristina Peixoto
Jan 26, 2021·Médecine sciences : M/S·Anne-Laure Hemonnot-GirardHélène Hirbec
Oct 29, 2020·Nature Reviews. Neuroscience·Alexander R Nectow, Eric J Nestler
Mar 30, 2020·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Wenfei LiuAhad A Rahim
Sep 3, 2020·Trends in Biotechnology·Qurrat Ul AinSarah Hedtrich
Apr 24, 2021·Frontiers in Neurology·Aristide MerolaKrystof Bankiewicz
Apr 30, 2021·Neurosurgery·Kelly M PothNicholas M Boulis
Jun 7, 2021·Biomaterials·Kevin CollonJay R Lieberman
Jul 13, 2021·Journal of Parkinson's Disease·Mark Tomishima, Agnete Kirkeby
Oct 27, 2020·Current Topics in Medicinal Chemistry·Josep GarciaMeritxell Teixidó
Aug 7, 2021·Journal of Personalized Medicine·Takayasu MishimaYoshio Tsuboi
Aug 10, 2021·Journal of Parkinson's Disease·Tomas Björklund, Marcus Davidsson
Aug 10, 2021·Journal of Parkinson's Disease·Amber D Van LaarKrystof S Bankiewicz
Apr 30, 2020·Molecular Therapy. Methods & Clinical Development·Anniina J ValkamaHanna P Lesch
Nov 7, 2020·Current Gene Therapy·Md Sahab UddinGhulam Md Ashraf
Oct 12, 2021·Frontiers in Neuroscience·Jonathan M Fischell, Paul S Fishman

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01856439

Software Mentioned

Quanticate
ProSavin

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.